AtomVie Supplies First Patient Dose in Radiopharm Theranostics' 177Lu-BetaBart Study

AtomVie Global Radiopharma, a leading global CDMO radiopharmaceutical company, announced that it has successfully provided the dosing of the first patient in Radiopharm Theranostics' Phase 1/2a clinical study of 177Lu-BetaBart (RV-01). AtomVie provided manufacturing and distribution services for the radiotherapeutic product, after successfully developing and qualifying the radiolabeling process and analytical methods using an appropriate phase-specific approach that accelerated the submission of the marketing authorization application. The Phase 1/2a study is designed as a dose-escalation and expansion trial evaluating the safety, biodistribution, radiation dosimetry, and preliminary anti-tumor activity of RV-01.